Core Viewpoint - The announcement by XinNuoWei regarding the approval of clinical trials for Dupilumab injection marks a significant step in the development of a biosimilar drug targeting IL-4Rα for the treatment of moderate to severe atopic dermatitis in adults [1] Company Summary - XinNuoWei's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for Dupilumab injection [1] - Dupilumab injection is a fully human monoclonal antibody drug and is classified as a biosimilar to Dupixent [1] Industry Summary - The drug is categorized under biological products for therapeutic use, specifically as a Class 3.3 application, indicating its relevance in the biopharmaceutical sector [1] - The indication for Dupilumab injection is aimed at treating adults with moderate to severe atopic dermatitis, highlighting the growing demand for effective treatments in this therapeutic area [1]
新诺威子公司度普利尤单抗注射液获药物临床试验批准